Month: September 2026

Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting

Posted on by Ravi Shankar

RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial’s primary endpoint

Meeting with FDA planned on October 1st to align on RAD101Phase 3 pivotal trial protocol

Brain Metastases Imaging has ~$600 million total addressable market, and there are no currently approved PET products

SYDNEY, Sept. 14, 2026 (GLOBE NEWSWIRE) — Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that positive data from an interim analysis of the Company’s Phase 2b imaging clinical trial (NCT06777433) of 18F-RAD101 (RAD101) in participants with suspected recurrent brain metastases from solid tumors has been selected for a late-breaking oral presentation at the  31st Annual Meeting of the Society of Neuro-Oncology (SNO26), taking place from November 12-15, 2026 in Philadelphia.

RAD101 is Radiopharm’s novel imaging small molecule targeting fatty acid synthase (FASN) radiolabelled with Fluorine-18 for the diagnosis of suspected recurrent brain metastases from solid tumors of different origins. The data from these findings will be used to support the initiation of a pivotal multi-center, global Phase 3 imaging trial.

“Having these data selected for a late-breaking oral presentation at SNO26 is a meaningful recognition of the potential clinical importance of RAD101,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. “The neuro-oncology community understands better than anyone the challenges associated with distinguishing active brain metastases from treatment effects using current imaging approaches. Knowing whether metastatic disease is present can fundamentally alter a patient’s treatment path and prognosis. We believe these data underscore RAD101’s potential to address a significant unmet need by helping physicians make more informed decisions and potentially changing the course of disease management for patients with suspected recurrent brain metastases.”

Previously reported results from the Phase 2b imaging trial of RAD101 for all assessed lesions showed 93% concordance between MRI and PET imaging of brain metastases in this patient population with suspected recurrence. The results showed substantial and selective tumor uptake of RAD101. Images confirm metabolic activity in PET compared to equivocal MRI findings. Additionally, 14 patients with evaluable six-month follow-up and/or biopsy data show preliminary 86% sensitivity, representing a strong positive trend (a secondary objective). Sensitivity measures an imaging test’s ability to correctly identify patients with disease.

In the U.S. alone, there are more than 300,000 patients diagnosed annually with cerebral metastases. The incidence of Intracranial Metastatic Disease (IMD) continues to increase, in part, due to improvements in systemic therapy resulting in a more durable control of the tumors outside of the central nervous system. Contrast-enhanced Magnetic Resonance Imaging (CE-MRI) is the preferred method for imaging IMD, but has limitations, particularly in follow-up surveillance scans to optimise patient care.1 

RAD101 has received U.S. Food and Drug Administration (FDA) Fast Track Designation to distinguish between recurrent disease and treatment effect of brain metastases originating from solid tumors of different origin including leptomeningeal disease. The company also recently announced a partnership with Siemens Healthineers, who will manufacture and distribute doses of 18F-labeled RAD101 to support Radiopharm’s upcoming Phase 3 pivotal trial in the U.S.

About the Phase 2b Clinical Trial of RAD101

The U.S. multi-center, open-label, single arm Phase 2b clinical trial is assessing the diagnostic
performance of 18F-RAD101 in 30 evaluable individuals with suspected recurrent brain metastases from solid tumors of different origins. The primary objective of the study is concordance between 18F-RAD101 PET-positive lesions and those equivocal lesions seen in conventional imaging (MRI with gadolinium) in participants with known brain metastases and suspected relapse after stereotactic radiosurgery (SRS). Secondary endpoints are sensitivity and specificity of RAD101 in identifying tumor recurrence versus radiation-associated changes in previously SRS-treated brain metastases.

About RAD101

RAD101 is the Company’s novel imaging small molecule that selectively binds to fatty acid synthase (FASN), a multi-enzyme protein that catalyses de-novo fatty acid synthesis and is overexpressed in cerebral metastasis from solid tumors. Targeting FASN activity may allow for the more accurate detection of cancer cells in the CNS, representing a clinically relevant method for the imaging of brain metastases. Positive data from the Imperial College of London’s Phase 2a imaging trial of 18F-RAD101 in patients with brain metastases (both SRS pre-treated and treatment naïve patients) showed significant tumor uptake that was independent from the tumor of origin. The study further indicated that PET-MRI may potentially represent a non-invasive prediction of overall-survival, warranting larger studies.

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and five Phase 1 trials in a variety of solid tumor cancers including lung, breast, prostate and brain. Learn more at radiopharmtheranostics.com.

Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.

For more information:

Investors:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Anne Marie Fields
Precision AQ (formerly Stern IR)
E: annemarie.fields@precisionaq.com

Media:
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
X – https://x.com/TeamRadiopharm  
LinkedIn – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/

1 A hybrid [18F]fluoropivalate PET-multiparametric MRI to detect and characterise brain tumour metastases based on a permissive environment for monocarboxylate transport | European Journal of Nuclear Medicine and Molecular Imaging

Posted in UncategorizedTagged

Satellogic to Launch Two ISL-Equipped Satellites and Sovereign Mark V in October

Posted on by Ravi Shankar

New Satellites Extend Inter-Satellite Link Architecture Across Satellogic’s Fleet and Add Capacity to the Company’s Sovereign Space Systems Program

PARIS, Sept. 14, 2026 (GLOBE NEWSWIRE) — Satellogic Inc. (NASDAQ: SATL), the infrastructure company for Persistent Global Intelligence (PGI), today announced that two new NewSat Mark VI satellites equipped with inter-satellite link (ISL) technology and one additional NewSat Mark V satellite will launch in October 2026.

The two Mark VI satellites extend Satellogic’s ISL architecture across a growing share of its fleet, allowing satellites to share information directly with one another in orbit. A detected change or object of interest on one satellite can inform the tasking of another without every decision passing through the ground first, shortening the data-to-decision timeline and ensuring the constellation operates as a connected, coordinated system.

The Mark V satellite adds capacity to Satellogic’s sovereign Space Systems program, which gives allied governments a pathway from commercial access to dedicated, sovereign-controlled capability. The launch builds on a body of proof points that includes Portugal’s purchase of a sovereign satellite, the company’s execution of the first commercial in-orbit transfer of a satellite, Tata’s operation of dedicated capacity for India, and HEO Australia’s first-of-its-kind sovereign capability.

“Launching these additional satellites builds out our Persistent Global Intelligence infrastructure with inter-satellite links that increasingly allow our satellites to work together as one coordinated system,” said Emiliano Kargieman, Chief Executive Officer of Satellogic. “The Mark V launch is a direct response to the growing demand we’re seeing from governments who want to own their intelligence capability. Our PGI infrastructure stack is optimized around the knowledge that mission assurance comes from compressing the time between something changing on the ground and the right decision-maker knowing about it.”

These new satellites reinforce how the company’s architecture is designed to operate as a coordinated stack. ISL-equipped Mark VI satellites carry detection into action faster, by allowing the constellation to communicate and retask itself in orbit. The Mark V satellite ensures that the same architecture is available to sovereign customers who need dedicated, controlled capacity rather than shared commercial access.

“With ISL, a detection on one satellite can inform the tasking of another without requiring every decision to pass through the ground first,” said Alan Kharsansky, Chief Technology Officer of Satellogic. “That’s the shift from operating independent satellites to running a connected network, one where the constellation itself prioritizes what matters and directs higher-resolution assets where they’re needed.”

This is one of a few releases Satellogic is putting out this week at World Space Business Week. The company also confirmed an expanded Slingshot III agreement with Innovative Defense Technologies and the U.S. Office of Naval Research and an update on the rendezvous and proximity operations (RPO) mission with HEO, in which Continuum-1, a Satellogic-built satellite never designed for close-approach work, was flown, on repurposed software and a modest fuel reserve, into a controlled orbit around an inactive rocket body.

About Satellogic

Founded in 2010, Satellogic (NASDAQ: SATL) builds the infrastructure for Persistent Global Intelligence (PGI): continuous, proactive awareness of the places, assets, and activities that matter. The company combines high-cadence satellite collection, best-in-class technology, AI-accelerated workflows, and sovereign-trusted architecture to help customers move from episodic imagery to persistent monitoring programs.

Satellogic serves allied defense and intelligence agencies, civil governments, and commercial markets that need reliable, scalable awareness of change across large portfolios of sites. Customers can begin with discovery, expand into persistent monitoring, and build toward dedicated or sovereign-controlled capacity as their mission requirements grow. To learn more, please visit: https://www.satellogic.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws. The words “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intends”, “may”, “might”, “plan”, “possible”, “potential”, “predict”, “project”, “should”, “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on Satellogic’s current expectations and beliefs concerning, among other things, our plans, strategies, prospects, both business and financial. Although we believe our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot give any assurance that we either will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. Many actual events and circumstances are beyond the control of the Company. Many factors could cause actual future results to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to generate revenue as expected, including due to challenges created by macroeconomic concerns, geopolitical uncertainty (e.g., trade relationships), financial market fluctuations and related factors, (ii) our ability to effectively market and sell our Persistent Global Intelligence (“PGI”) services and to convert contracted revenues and our pipeline of potential contracts into actual revenues, (iii) market acceptance of our PGI services and our dependence upon our ability to keep pace with the latest technological advances, including those related to artificial intelligence and machine learning; (iv) risks related to the secured convertible notes, (v) the potential loss of one or more of our largest customers, (vi) the considerable time and expense related to our sales efforts and the length and unpredictability of our sales cycle, (vii) risks and uncertainties associated with defense-related contracts, (viii) risk related to our pricing structure, (ix) our ability to scale production of our satellites as planned, (x) unforeseen risks, challenges and uncertainties related to our expansion into new business lines, (xi) our dependence on third parties, including SpaceX, to transport and launch our satellites into space, (xii) our reliance on third-party vendors and manufacturers to build and provide certain satellite components, products, or services and the inability of these vendors and manufacturers to meet our needs, (xiii) our dependence on ground station and cloud-based computing infrastructure operated by third parties for value-added services, and any errors, disruption, performance problems, or failure in their or our operational infrastructure, (xiv) risk related to certain minimum service requirements in our customer contracts, (xv) our ability to identify suitable acquisition candidates or consummate acquisitions on acceptable terms, or our ability to successfully integrate acquisitions, (xvi) competition for PGI services, (xvii) risks related to changes in tax laws and regulations, including the “One Big Beautiful Bill Act,” (xviii) risks related to changes in trade policy and the related impact on macroeconomic conditions, including further expansions of U.S. export controls and tariffs, as well as related retaliatory actions, (xix) challenges with international operations or unexpected changes to the regulatory environment in certain markets, (xx) unknown defects or errors in our products, (xxi) risk related to the capital-intensive nature of our business and our ability to raise adequate capital to finance our business strategies, (xxii) uncertainties beyond our control related to the production, launch, commissioning, and/or operation of our satellites and related ground systems, software and analytic technologies, (xxiii) the failure of the market for PGI services to achieve the growth potential we expect, (xxiv) risks related to our satellites and related equipment becoming impaired; (xxv) risks related to the failure of our satellites to operate as intended, (xxvi) production and launch delays, launch failures, and damage or destruction to our satellites during launch, and (xxvii) the impact of natural disasters, unusual or prolonged unfavorable weather conditions, epidemic outbreaks, terrorist acts and geopolitical events (including the ongoing conflicts between the United States and Iran, Russia and Ukraine, and in the Gaza Strip) on our business and satellite launch schedules. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Satellogic’s Annual Report on Form 10-K and other documents filed or to be filed by Satellogic from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Satellogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Satellogic can give no assurance that it will achieve its expectations.

Contacts

Satellogic Investor Relations:
ir@satellogic.com

Satellogic Media Relations:
pr@satellogic.com

Posted in UncategorizedTagged

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

Posted on by Ravi Shankar

Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy

Initial data is expected in 2027

WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) — Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the first patient has been dosed in its Phase 2 basket trial evaluating ebribafusp for the treatment of rare complement-mediated kidney diseases, including IgA nephropathy (IgAN), lupus nephritis (LN), and C3 glomerulopathy (C3G). Ebribafusp is an investigational, next-generation anti-C3d factor H fusion protein designed to inhibit complement activation in tissues without inhibiting the complement system in the blood. The Phase 2 basket trial is open-label, and Akebia expects to report initial data in 2027.

“Dosing the first patient in this basket trial is an important milestone for the ebribafusp program and, more importantly, for patients living with rare kidney diseases,” said Dr. Steven Burke, Chief R&D and Medical Officer at Akebia. “Ebribafusp is designed to inhibit complement activation directly in kidney tissue without suppressing the complement system in the blood. If successful, we believe this differentiated approach has the potential to provide patients with a long-term treatment option while reducing the infection risk associated with systemic complement inhibition and could have applicability across multiple rare kidney diseases.”

The Phase 2 basket trial is designed to evaluate the safety, efficacy, and pharmacokinetics of ebribafusp and is expected to enroll up to 30 patients with IgAN, LN or C3G. Patients will receive ebribafusp dosed once-weekly subcutaneously for 26 weeks in the main study followed by a long-term extension study for responders. The primary endpoint is the incidence of adverse events, and secondary endpoints include change in proteinuria measured by urine protein creatinine ratio (UPCR), kidney function measured by estimated glomerular filtration rate (eGFR), and pharmacokinetics. The trial will also measure blood and urine complement biomarkers to assess the extent that ebribafusp reduces complement activity in kidney tissue without inhibiting the complement system in the blood.

Additional information about the trial is available at ClinicalTrials.gov under identifier NCT06419205.

About Ebribafusp
Ebribafusp (previously referred to as AKB-097 and ADX-097), an anti-C3d factor H fusion protein, is an investigational, next-generation complement inhibitor. The presence of C3d in glomeruli is a hallmark of numerous complement-mediated kidney diseases. Ebribafusp is designed to target the sites of complement activation in tissues to inactivate the alternative pathway C3 convertase. Ebribafusp is being studied with the goal of targeting local, uncontrolled complement activity and inflammation at the site of kidney injury.

In November 2025, Akebia acquired the global rights to ebribafusp from Q32 Bio, Inc. (Q32 Bio). In nonclinical studies conducted by Q32 Bio, ebribafusp distributed to affected tissues and organs and demonstrated durable tissue pharmacokinetic and pharmacodynamic properties. In a completed Phase 1 clinical trial in healthy volunteers conducted by Q32 Bio, ebribafusp was observed to be generally well-tolerated and demonstrated minimal anti-drug antibodies.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Waltham, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release. 

Forward-Looking Statements
Statements in this press release regarding Akebia Therapeutics, Inc.’s (“Akebia’s”) strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and include, but are not limited to: Akebia’s beliefs and expectations regarding the potential benefits and mechanism of action of ebribafusp, including its potential to inhibit complement activation directly in kidney tissue without suppressing the complement system in the blood, its ability to target the sites of complement activation in tissues to inactivate the alternative pathway C3 convertase, and its ability to target local, uncontrolled complement activity and inflammation at the site of kidney injury; Akebia’s beliefs that ebribafusp represents a differentiated approach that, if successful, has the potential to provide patients with a long-term treatment option while reducing the infection risk associated with systemic complement inhibition; Akebia’s beliefs that ebribafusp could have applicability across multiple rare kidney diseases; Akebia’s beliefs and expectation regarding the initiation of the Phase 2 basket trial, including the potential benefit for patients living with rare kidney diseases; and Akebia’s goals and expectations regarding the Phase 2 basket trial, including its ability to demonstrate safety, efficacy and pharmacokinetics, the number of patients to be enrolled and the timing of reporting initial data from the trial.

The terms “intend,” “believe,” “plan,” “goal,” “potential,” “anticipate,” “estimate,” “target,” “predict,” “expect,” “future,” “may,” “will,” “could,” “continue,” derivatives of these words, and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks, uncertainties and other factors, including, but not limited to, risks associated with: the potential therapeutic benefits, safety profile, and effectiveness of Akebia’s products and product candidates; risks and uncertainties related to Akebia’s ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials, the ability to enroll patients in and the timing of such preclinical studies and clinical trials; the results of Akebia’s preclinical studies and clinical trials, including that initial, preliminary, interim or retrospective data, analysis or results may not be replicated in, or predictive of, final analyses or results of future preclinical or clinical data, analyses or results or that such analysis or results may not support further development of such product candidates; decisions made by health authorities, such as the FDA, with respect to regulatory filings and other interactions; the potential demand and market potential and acceptance of, as well as coverage and reimbursement related to Akebia’s commercial products, including estimates regarding the potential market opportunity; the competitive landscape for Akebia’s commercial products, including generic entrants and the timing thereof; Akebia’s ability to obtain and maintain patent protection on its products and product candidates, and to successfully defend these patents against third-party challenges; Akebia’s ability to attract and retain qualified personnel; Akebia’s ability to achieve and maintain profitability and to maintain operating expenses consistent with its operating plan; Akebia’s revenue and that its financial results from prior periods may not be indicative of future results; manufacturing, supply chain and quality matters and any recalls, write-downs, impairments or other related consequences or potential consequences; early termination of any of Akebia’s collaborations; and changes in the geopolitical environment and uncertainty surrounding U.S. trade policy on tariffs. Other risks and uncertainties include those identified under the heading “Risk Factors” in Akebia’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC), and other filings that Akebia may make with the SEC in the future. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and, except as required by law, Akebia does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this press release.

Akebia Therapeutics® is a registered trademark of Akebia Therapeutics, Inc. and its affiliates.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

Posted in UncategorizedTagged

Disclosure of trading in own shares from September 7, 2026 to September 11, 2026

Posted on by Ravi Shankar

Head Office : 39, Esplanade du Général de Gaulle 92800 Puteaux La Défense, France  
Tel : + 33 (0) 1 59 23 65 00 – www.nexans.com  
a French Société Anonyme with a share capital of € 43,746,793 – R.C.S. Nanterre 393 525 852 – Id VAT FR 74 393 525 852  
                         
Disclosure of trading in own shares                    
From September 7 to 11, 2026                    
Issuer : Nexans                      
Category : treasury shares                      
                         
Pursuant to applicable law on share buybacks, Nexans declares the following purchases of its own shares from September 7, 2026 to September 11, 2026  
                         
The trades have been executed within the framework of the description of the buyback program published on April 2nd, 2026, on the Company’s website (www.nexans.com) by an investment firm pursuant to a mandate.  
                         
Name of the Issuer Identity Code of the Issuer Day of the transaction Identity Code of Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code)            
NEXANS 96950015FU78G84UIV14 9/7/2026 FR0000044448 3 000 138.9970 XPAR            
NEXANS 96950015FU78G84UIV14 9/8/2026 FR0000044448 3 000 139.9176 XPAR            
NEXANS 96950015FU78G84UIV14 9/9/2026 FR0000044448 3 000 139.1184 XPAR            
NEXANS 96950015FU78G84UIV14 9/10/2026 FR0000044448 3 000 139.3464 XPAR            
NEXANS 96950015FU78G84UIV14 1109/2026 FR0000044448 3 000 142.2984 XPAR            
      TOTAL 15,000                
                         
Name of the issuer Identity Code of the Issuer Name of the Broker Identity Code of the Broker Day/time of the transaction (Paris Time) Identity Code of the financial instrument Quantity bought Price per unit Currency Identity Code of the Market Reference number of the transaction Purpose of the buyback  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 09:01:05 FR0000044448 70 138.3000 EUR XPAR 6O1jOr8BT6CcDTrP3ubPUwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 09:15:17 FR0000044448 82 138.4000 EUR XPAR NVg2WVhJTBaP5yeyGhTdTwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 09:15:17 FR0000044448 85 138.4000 EUR XPAR 6OeRkw2VRYy_Tm61h1uOZQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 09:23:31 FR0000044448 76 138.1000 EUR XPAR NWShIy3PRX-1IGbVDYx2owA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 09:56:04 FR0000044448 194 139.1000 EUR XPAR oEW28_0oSbOqs50DN4XDeQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 10:35:38 FR0000044448 136 139.6000 EUR XPAR lv2wvEi9SjG3kAhOCQS4OgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 10:35:38 FR0000044448 70 139.5000 EUR XPAR aG_cMUY1RMqDTFucPhHoPAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 11:06:08 FR0000044448 55 139.2000 EUR XPAR XK4aRqu2Q1-zw4iAIg6aSgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 11:06:08 FR0000044448 16 139.2000 EUR XPAR lR_eJ3kGSK6NV4xc7i_6UQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 11:06:08 FR0000044448 4 139.2000 EUR XPAR tLg0ggt2T5OVpMU9yXcjWAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 11:29:36 FR0000044448 140 139.0000 EUR XPAR gFmtajKGQHKVudUgdR8dtQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 11:59:43 FR0000044448 154 139.1000 EUR XPAR C94hOCJiT_OPqG-S_A_OtwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 12:37:30 FR0000044448 182 139.2000 EUR XPAR He_VKvGrSdK6NiIVcDR-tgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 13:20:31 FR0000044448 52 138.7000 EUR XPAR WZ6URpA1Te6D13_hXQGQHwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 13:51:52 FR0000044448 1 138.6000 EUR XPAR iXsKnyiARbW29F-aKQEHtwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 13:51:52 FR0000044448 167 138.6000 EUR XPAR nU9ILmogSZWgOh461kE71wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 13:59:17 FR0000044448 70 138.6000 EUR XPAR nziB_E3SSu6atsQKffPZYgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 14:25:34 FR0000044448 6 138.8000 EUR XPAR rRX63chpQDSYejtyF9JJZgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 14:36:55 FR0000044448 157 138.8000 EUR XPAR 0ywYCHgFQY2u5-eHSqSyCwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 14:49:07 FR0000044448 71 138.7000 EUR XPAR vt9HAjbeTbaRyTwgwvPLhQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 15:31:32 FR0000044448 24 139.2000 EUR XPAR kqEGhxMWQQuelEt3pJR7cwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 15:31:32 FR0000044448 46 139.2000 EUR XPAR N5tR2ZPZSjSvWtVjp6na4QA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 15:33:46 FR0000044448 75 139.2000 EUR XPAR 2ELfOgU-QgqFTKcC2iEnjwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 15:36:56 FR0000044448 17 139.3000 EUR XPAR DqydgrxMTOiqrbMW3iLoDwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 15:36:56 FR0000044448 26 139.3000 EUR XPAR hIBcroQkS1OmFIC8vpHP-wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 15:36:56 FR0000044448 14 139.3000 EUR XPAR 6rva_cmGQE2I8Bu15nNYgAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 15:36:56 FR0000044448 23 139.3000 EUR XPAR ui9aH0AETVKHAWFT5CsYpAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 15:45:59 FR0000044448 101 139.2000 EUR XPAR QYj1VIiJRCyad-uLq1n1HAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 15:45:59 FR0000044448 14 139.2000 EUR XPAR AxA8BZidSzCdZxNDEB7CagA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 15:45:59 FR0000044448 14 139.2000 EUR XPAR fkoGYx8CR22OP1_EFCARmgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 16:04:33 FR0000044448 4 139.5000 EUR XPAR b0OMf2FdQeGKN-P3SMqTzAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 16:04:33 FR0000044448 8 139.5000 EUR XPAR dlab-TcoQ9mAhJIKt0sDMgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 16:05:24 FR0000044448 159 139.5000 EUR XPAR 3st5Gu4iSRymPbt4lJ6C-AA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 16:18:07 FR0000044448 80 139.3000 EUR XPAR ya1kpgULSJ2Qy2336z2DsgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 16:23:47 FR0000044448 86 139.2000 EUR XPAR WXF2CIx5SJuH_-Pty5LPVgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 16:29:32 FR0000044448 17 139.1000 EUR XPAR 6Tvv14PJTCyW0c7PTEZfsQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 16:29:32 FR0000044448 16 139.1000 EUR XPAR uWjZF8UqS96dx5pqgEo98AA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 16:29:32 FR0000044448 52 139.1000 EUR XPAR 0RDy6A-PTRmn9RVlbPSlIwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 16:38:29 FR0000044448 62 138.9000 EUR XPAR 8RrDaz5vRYyfwvYIPp9rdQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 16:50:58 FR0000044448 96 138.9000 EUR XPAR lsP-6M5ZRQmDdqf_9IatwAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 17:01:33 FR0000044448 135 138.9000 EUR XPAR DbMbwLEqSEu0i_T8aTjm3wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 17:01:33 FR0000044448 5 138.9000 EUR XPAR q8oxZFU-SM6zBy8kREVY3gA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 17:14:38 FR0000044448 17 138.9000 EUR XPAR 3447926543045 MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 17:14:38 FR0000044448 17 138.9000 EUR XPAR 3447926544045 MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 17:14:38 FR0000044448 3 138.9000 EUR XPAR 3447926545045 MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 17:14:38 FR0000044448 79 138.9000 EUR XPAR 3447926546045 MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 17:14:38 FR0000044448 21 138.9000 EUR XPAR 3447926547045 MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 07/09/2026 17:15:20 FR0000044448 1 138.9000 EUR XPAR 3447928252045 MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 09:00:30 FR0000044448 18 137.8000 EUR XPAR KtWgC-JOR4e9hxctQZSHzwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 09:06:11 FR0000044448 70 138.3000 EUR XPAR 8p2btZe6TY2urWBCyKHi3AA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 09:12:12 FR0000044448 68 138.3000 EUR XPAR e5PK7bf5RV-quDKY7pvMJAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 09:20:57 FR0000044448 78 138.4000 EUR XPAR ZNE6N5gGTwGIEpJBvUyfbgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 09:33:44 FR0000044448 82 138.3000 EUR XPAR K-pmcuraS-i74lTdCHkv2wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 09:46:20 FR0000044448 16 138.4000 EUR XPAR IS6ByfBqTcKKQfnjzbiO8QA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 09:46:20 FR0000044448 12 138.4000 EUR XPAR e9cdBujwQHm6ioY5IUvKHwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 09:46:20 FR0000044448 61 138.4000 EUR XPAR fpFnx-ZbR1OXbz3dqiYnEQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 09:46:20 FR0000044448 88 138.3000 EUR XPAR HsmAzG94RyCEJsN5VnZXuQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 10:02:07 FR0000044448 18 137.9000 EUR XPAR M5axlltBSZKDuMwwSBYJ9wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 10:29:25 FR0000044448 81 138.6000 EUR XPAR Ey-D0dgETVaYyO__FeZLIQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 10:41:21 FR0000044448 69 138.5000 EUR XPAR 4CVU1EHfT6mIr4rA0cBF3AA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 10:51:37 FR0000044448 80 138.7000 EUR XPAR MUeP0qT_Tv69hkIkhQeUNwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 11:11:32 FR0000044448 131 139.2000 EUR XPAR DK_6HYwsTfWE4PpTgC5WBgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 11:11:32 FR0000044448 26 139.2000 EUR XPAR ji0KVXxzQjWwNqW7y_y1CQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 11:36:59 FR0000044448 133 139.7000 EUR XPAR cv9JleJOSy6aemZsNro3tgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 12:27:36 FR0000044448 63 140.4000 EUR XPAR Uspdms1jQku4huhLYYgNlgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 12:27:36 FR0000044448 18 140.4000 EUR XPAR InVYglc5Tc2kOQjrIV4Q_wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 12:51:36 FR0000044448 43 140.4000 EUR XPAR VXm1035YRwuV-fbaNrRkBwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 12:51:36 FR0000044448 24 140.4000 EUR XPAR d2q93RYBQ326phrIB-XwEgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 12:59:14 FR0000044448 183 140.3000 EUR XPAR rZGmTE4DSVCe4Rl3K0xKjAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 13:25:13 FR0000044448 58 140.3000 EUR XPAR d5Kze-FnRES0hbJh-Y2e6gA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 14:00:07 FR0000044448 88 140.1000 EUR XPAR mkEpBd1IQpyTeVrpoZ49DgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 14:00:07 FR0000044448 72 140.1000 EUR XPAR wH634327TaaJyB7XXNbnYgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 14:50:13 FR0000044448 144 140.1000 EUR XPAR _wUpEmFKTHKEO8JzvGlKngA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 15:02:50 FR0000044448 81 140.1000 EUR XPAR THaU3BHpRAyBL3fLWo-KTQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 15:29:09 FR0000044448 219 140.6000 EUR XPAR iB_PHKlCTdaEiv9H8_ZalAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 15:47:24 FR0000044448 153 140.8000 EUR XPAR YurX7m5hRzeQBHZKllqJHAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 16:05:15 FR0000044448 69 140.5000 EUR XPAR OoJOws04Qj-IX3XypOsuAgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 16:05:21 FR0000044448 21 140.4000 EUR XPAR BpOS0VHdQha13DmG0Wlb6wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 16:05:21 FR0000044448 46 140.4000 EUR XPAR l0I8eiwbSzqW0vSy7N-NGAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 16:17:12 FR0000044448 70 139.9000 EUR XPAR EPyojlTETMSzZ-dsUylwMAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 16:33:16 FR0000044448 70 140.7000 EUR XPAR l404siAKQWyIJSvGEVtg2gA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 16:34:27 FR0000044448 77 140.6000 EUR XPAR N_ZQ1Gs2TiiKbhyxqHqxKQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 16:47:32 FR0000044448 76 140.9000 EUR XPAR -ftRcu2ETtWWeqFTr0kKbAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 16:55:46 FR0000044448 60 141.0000 EUR XPAR LoJty4zTT323jI6DB7SwugA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 16:55:46 FR0000044448 78 141.0000 EUR XPAR QsnQPJr1SKCTy1HOIRX-dAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 17:08:36 FR0000044448 141 141.1000 EUR XPAR 1lRzcKWFQJegKhfsvX9nIgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 17:27:44 FR0000044448 9 141.5000 EUR XPAR 3449096140045 MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 17:27:44 FR0000044448 63 141.5000 EUR XPAR 3449096141045 MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 08/09/2026 17:27:44 FR0000044448 43 141.5000 EUR XPAR 3449096142045 MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 09:03:00 FR0000044448 136 141.2000 EUR XPAR EKfHi-jJQ4Sb6pkwUO5SyAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 09:22:05 FR0000044448 70 141.4000 EUR XPAR 8ro-voZ0QYaZy2kzDA4xXwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 09:30:09 FR0000044448 70 141.6000 EUR XPAR 2oUZhNLPSeinlt-aJt_qIwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 09:40:30 FR0000044448 73 141.1000 EUR XPAR rS22Nx27TNmkbFYf9q7mDAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 09:50:02 FR0000044448 3 141.0000 EUR XPAR GEEzZKJWQ_WOIv2AtJuvbgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 09:50:02 FR0000044448 74 141.0000 EUR XPAR m-Xrjr0ZSrmNLtg3IPz47gA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 09:50:02 FR0000044448 76 141.0000 EUR XPAR cmoUCnp9Qr-QzbM_UU77JgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 10:03:05 FR0000044448 77 140.9000 EUR XPAR 9ykz7iZoQcWq3H6eTH-4kQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 10:10:01 FR0000044448 33 140.9000 EUR XPAR _RNDNoTDSs6IezQu4arsTAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 10:10:01 FR0000044448 45 140.9000 EUR XPAR S4yckPR8RiqL5rnG9CsxEgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 10:36:25 FR0000044448 73 140.1000 EUR XPAR LXHCi7fuTKCySnGpx6Cn0wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 10:58:48 FR0000044448 144 139.9000 EUR XPAR JtIWVTw5Rue7eO9nHbga-QA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 11:16:52 FR0000044448 75 139.9000 EUR XPAR RoGNMS8xSXqM39owbrs9NQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 11:31:40 FR0000044448 72 139.2000 EUR XPAR n2VjmIPASNqlY-QXA90x5AA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 11:44:12 FR0000044448 68 138.9000 EUR XPAR bm5Llc7GS6CFdc5WlIMGHgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 12:15:36 FR0000044448 79 138.1000 EUR XPAR nqfZ6pSqSja5eA9guLLDOwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 12:57:15 FR0000044448 30 137.8000 EUR XPAR Ofghrf7XRCa9RrU7sSD4twA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 12:57:15 FR0000044448 57 137.8000 EUR XPAR 5c7h4Sj5R-2SYb9nM7aWGAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 12:57:15 FR0000044448 1 137.8000 EUR XPAR 7rPhAo7oShSKSvY7JtP0gAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 12:57:15 FR0000044448 2 137.8000 EUR XPAR _DSRVuAFQ6ar_keRZpkNJwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 13:26:37 FR0000044448 23 138.2000 EUR XPAR hAx26RxARzi97Ce1eaJHKQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 13:26:37 FR0000044448 57 138.2000 EUR XPAR yCy2JsaNRauvUHf5VBsrHQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 13:26:37 FR0000044448 62 138.2000 EUR XPAR CzQUxxiUTsa2EI4TKHduGQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 13:45:27 FR0000044448 29 137.9000 EUR XPAR LLgFlFKJR9WfNyBbO6lgwQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 14:16:39 FR0000044448 81 138.1000 EUR XPAR SSvxMGBQR6KJonbG0neXgAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 14:16:39 FR0000044448 148 138.0000 EUR XPAR r4CEI4D2SjWuqzr8sDkB9gA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 14:55:22 FR0000044448 164 138.5000 EUR XPAR Ey4cAMN0QxWHgq1RHSODWwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 15:23:54 FR0000044448 153 138.6000 EUR XPAR Dykpf_1lST61i_Ga9TuOyAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 15:36:26 FR0000044448 56 139.2000 EUR XPAR 9mF5P7TgQmG2RLHVO_Cg8wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 15:36:26 FR0000044448 12 139.2000 EUR XPAR sRyHJ7ZZSKavp0sgFIW-BQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 15:36:26 FR0000044448 69 139.2000 EUR XPAR msyzdbKgST2YVcsdD66RtAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 15:55:52 FR0000044448 77 139.3000 EUR XPAR 2etUJ4sCRHKH1z-G50zklwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 16:01:45 FR0000044448 55 139.0000 EUR XPAR KB1-qBlARqSqtGyR_ji6bAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 16:01:45 FR0000044448 23 139.0000 EUR XPAR c1qe5sLIRUiC3BHo7uU0fAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 16:01:50 FR0000044448 49 138.9000 EUR XPAR 11UFNh7nRemsEbbgspt09wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 16:01:50 FR0000044448 28 138.9000 EUR XPAR XsxfJhVARQO4b9gcDJ_oIwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 16:19:11 FR0000044448 79 138.3000 EUR XPAR J5F-EZ5YRyuRbJcsOfoR9gA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 16:31:19 FR0000044448 78 138.4000 EUR XPAR xzH2RO2DQo-tOA8JcFi7UQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 16:37:02 FR0000044448 67 138.2000 EUR XPAR QjmQgwlGQTCtBAOeBowNTAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 16:50:09 FR0000044448 165 137.8000 EUR XPAR Ev3qHVHDT6SlB6EHoISyVwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 17:01:04 FR0000044448 69 137.9000 EUR XPAR 7K36EXC3S4qND4-sua_4-AA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 17:13:39 FR0000044448 69 137.7000 EUR XPAR dsdeWS2wSJaWsWu_WC08yAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 09/09/2026 17:25:09 FR0000044448 129 137.7000 EUR XPAR 3450358259045 MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 09:01:31 FR0000044448 68 138.8000 EUR XPAR GiVrg8keT2a1ODA6mZzzgwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 09:08:02 FR0000044448 80 138.9000 EUR XPAR -dR02LUNRtuSRHl1xkUxbQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 09:08:51 FR0000044448 71 138.7000 EUR XPAR imD7U9dCRoeK2ReBwcboIwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 09:28:53 FR0000044448 68 138.6000 EUR XPAR LXOa7q98TTyRGs1YbSwnQwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 09:30:52 FR0000044448 67 138.5000 EUR XPAR A7QebPVxQbOsuvuEJV3vpwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 09:48:30 FR0000044448 132 138.3000 EUR XPAR _mmUmtOhQY-ml_ceZN_K3gA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 10:04:37 FR0000044448 67 138.7000 EUR XPAR 243oEr1ASTWgOLHjMT7s0AA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 10:37:56 FR0000044448 25 139.2000 EUR XPAR MNIyyi-0SW21C0MeFE0oGgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 10:37:56 FR0000044448 25 139.2000 EUR XPAR OwH5OsCyR72BzSSiBOk5JwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 10:37:56 FR0000044448 8 139.2000 EUR XPAR ivgpIMRAQf2YPOjw0pxLQwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 10:37:56 FR0000044448 67 139.2000 EUR XPAR wnkBjmkDQv2XsaBEpKobjQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 10:37:56 FR0000044448 25 139.2000 EUR XPAR 5A2TEtRpTkySPyzBKadIegA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 10:37:56 FR0000044448 67 139.2000 EUR XPAR 7oKsoziTRfewzqJ9ka5wJQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 11:08:32 FR0000044448 69 142.3000 EUR XPAR IJXmI496QJC3N_x-OVk3-gA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 11:08:32 FR0000044448 72 142.2000 EUR XPAR bZ1otSgdQlKu7ZzW-DyNnwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 11:49:09 FR0000044448 71 142.1000 EUR XPAR aqnvNw08S5KaRR8P_7R83QA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 12:08:01 FR0000044448 81 141.7000 EUR XPAR PMyT9DtfQQmgR0kVeub_rwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 12:09:24 FR0000044448 84 141.1000 EUR XPAR xRZ_h9tOSaqR3V5ziBYmUwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 12:30:48 FR0000044448 77 140.5000 EUR XPAR zku15TuhTTyGcnDrxdgBHAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 13:22:04 FR0000044448 70 140.9000 EUR XPAR p_EDR4jcRpyhdgqyqMsTPgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 13:22:04 FR0000044448 3 140.9000 EUR XPAR yA7jc4BzTseJ5KS1W51BXgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 13:32:28 FR0000044448 82 140.6000 EUR XPAR 4sUdvFDeSPuXOmkbQAn6ZwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 13:32:28 FR0000044448 72 140.6000 EUR XPAR loNoep6rTzmOx_skZnuInQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 14:15:42 FR0000044448 149 139.9000 EUR XPAR M1DJVGpJTjyLMia1Ibpr5QA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 14:22:33 FR0000044448 72 139.5000 EUR XPAR TjdO22mtQM2iDWDoQsqgnAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 14:38:07 FR0000044448 68 138.9000 EUR XPAR nnXjXoZxTRG7Jxkliy_w7wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 14:56:24 FR0000044448 67 138.3000 EUR XPAR rOGHmF_nS8mSJTL2AA6IugA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 15:01:37 FR0000044448 73 138.2000 EUR XPAR yML70HP_RxivCThE2xlfKAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 15:30:17 FR0000044448 79 138.1000 EUR XPAR dpBxlH5JTVywzFteCNzDQQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 15:41:49 FR0000044448 70 139.1000 EUR XPAR rrC-tn-2QuysHv7rmPWnBgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 15:46:11 FR0000044448 43 138.4000 EUR XPAR ag9nUMhbSHOPXz1x9J9SMwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 15:51:09 FR0000044448 78 138.3000 EUR XPAR M3H4XeHKSze256xiw32BIAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 16:03:13 FR0000044448 75 138.6000 EUR XPAR H55AJcr4S5igS_mZY6juAwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 16:07:57 FR0000044448 58 138.1000 EUR XPAR GTa8cUj-T_igbtSLrJhPsgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 16:07:57 FR0000044448 23 138.1000 EUR XPAR QqgfE3YyQBOPTJ6AbWcKsQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 16:13:53 FR0000044448 78 138.1000 EUR XPAR dhn2iXPNQzulvhhdFAMrQAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 16:13:53 FR0000044448 82 138.0000 EUR XPAR dvkTsBU9SrSQMN31lMatMQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 16:35:25 FR0000044448 81 138.2000 EUR XPAR kLwn5uA6QSCAGlYTpjGCYQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 16:47:55 FR0000044448 18 138.6000 EUR XPAR cPU-CCXPRu6dpJLmp36d7QA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 16:47:55 FR0000044448 62 138.6000 EUR XPAR wbM_yl2ZS3qAWIARy5MLqgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 16:52:10 FR0000044448 75 138.8000 EUR XPAR I2021CajSU6piSDRvJRsnwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 17:00:32 FR0000044448 71 138.9000 EUR XPAR N34S6T56QEi7cEgOLP8tWAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 17:09:16 FR0000044448 73 139.2000 EUR XPAR yFGbAfkDQpWkg5TkV4hRxgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 17:16:34 FR0000044448 69 139.6000 EUR XPAR ZJejFKauTzGSfW4SWjkBPQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 17:24:33 FR0000044448 37 139.5000 EUR XPAR 2_9IACeLThSskPaZgy0f6wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 10/09/2026 17:24:33 FR0000044448 48 139.5000 EUR XPAR 05duKxUDR16DkiXmbXUQBwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 09:00:30 FR0000044448 17 139.7000 EUR XPAR -HjJYJ_YTtmTre81Zod-cgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 09:00:51 FR0000044448 68 139.6000 EUR XPAR fgtafL7LTl-7knp0OkFBvQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 09:11:18 FR0000044448 86 139.7000 EUR XPAR bHhxHWPOQYKhyaiGZy4jVQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 09:22:41 FR0000044448 79 140.7000 EUR XPAR lm-UvIlxQQWUZTM7AqsEugA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 09:25:23 FR0000044448 89 140.5000 EUR XPAR AnWLERqOQMuYN4ORnGGPggA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 09:49:07 FR0000044448 62 140.8000 EUR XPAR rTCEsbOyTAqhU_vBDCw2uAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 09:49:07 FR0000044448 25 140.8000 EUR XPAR utdnj-gzTOiAVWAlKb796gA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 09:49:07 FR0000044448 89 140.9000 EUR XPAR yvFVR3AfSdmlXjukBIDFtAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 10:24:49 FR0000044448 87 141.0000 EUR XPAR -qEalFgPQj-sttVXo8P6NQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 10:32:02 FR0000044448 102 140.9000 EUR XPAR jukyRDEyR8OF-MJolOUS8wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 10:33:01 FR0000044448 4 140.7000 EUR XPAR Q0El5ZVuTKGZD1U3nNikGQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 10:33:01 FR0000044448 70 140.7000 EUR XPAR ofUyJtC1SruJf55tsP-yWAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 11:08:18 FR0000044448 74 140.2000 EUR XPAR ErS6AuugRCKJkipz0z57mQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 11:08:18 FR0000044448 6 140.2000 EUR XPAR MLj9OzejQ_SGRKywdxSkbQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 11:08:18 FR0000044448 3 140.2000 EUR XPAR enmnaLKDQH-5D_oFJ37a3gA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 11:08:18 FR0000044448 12 140.2000 EUR XPAR WxKujE3BQV-pyr2Q5ISELAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 11:25:32 FR0000044448 140 140.3000 EUR XPAR xP_SJT0jTnmdfTYjZE_rAwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 11:44:03 FR0000044448 79 140.0000 EUR XPAR eXVmLYuwQ8iZEAP06yPI4wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 12:01:36 FR0000044448 72 140.1000 EUR XPAR VB45__fMSniKgWyRf6AfDgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 12:58:29 FR0000044448 99 141.8000 EUR XPAR pNQVmws2TWupzwQiiaVHmwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 13:10:04 FR0000044448 86 141.5000 EUR XPAR 26y0DoRJTaytrJXSr18NkQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 13:10:04 FR0000044448 76 141.5000 EUR XPAR AC-GL8KJQ8OKb7gx_Xgz-gA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 13:56:37 FR0000044448 68 142.3000 EUR XPAR pVMvByBCTA-uGzIUhfVlEQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 13:56:37 FR0000044448 70 142.3000 EUR XPAR u1RJSSFASUuSN6lJUg7jbgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 14:30:01 FR0000044448 80 142.3000 EUR XPAR hKj-IiopS0-lGbLoMbK0ZQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 14:30:01 FR0000044448 75 142.3000 EUR XPAR rlfWVoDPTjmuotn9yZsK5AA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 15:04:20 FR0000044448 68 144.2000 EUR XPAR 19Mlc5AOTNydJSU_GWUZEAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 15:18:34 FR0000044448 70 144.4000 EUR XPAR dNU4y5YJRP2ritnem9FgewA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 15:27:23 FR0000044448 86 144.1000 EUR XPAR qoiTuwfHTqCTEZ8sjhUf4QA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 15:27:24 FR0000044448 82 144.0000 EUR XPAR F7YGUhC4S7yTzwU6FGtVcQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 15:47:11 FR0000044448 90 145.6000 EUR XPAR 1qCq9GWuR-W8UxresfIz7wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 15:55:39 FR0000044448 72 145.2000 EUR XPAR 5TKEyDO_Q5-81mGY2fMn3QA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 15:58:22 FR0000044448 68 144.8000 EUR XPAR S6GLnHDrSSmr5Qetctb0gwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 15:58:22 FR0000044448 67 144.7000 EUR XPAR vFizzM5bSrOPqhT9mNs5VQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 16:15:15 FR0000044448 72 144.3000 EUR XPAR 6yfGnkwmR9uwZSLNYThwOAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 16:28:05 FR0000044448 67 144.1000 EUR XPAR APLxTkXDS2KjM80T6TSHBAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 16:37:39 FR0000044448 68 143.8000 EUR XPAR C4CkH1WeQLKF6O8MzE3iPAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 16:38:03 FR0000044448 51 143.7000 EUR XPAR AI6x_elNQzGOD6l3SzmBHQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 16:38:03 FR0000044448 29 143.7000 EUR XPAR N88pNAf5QWWxCitd3rYaoAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 16:51:39 FR0000044448 148 143.6000 EUR XPAR T3T_K_TVTpK3wq87-7IfLQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 17:11:51 FR0000044448 75 143.4000 EUR XPAR jnSUPT68Rbi2u-ZZxkDrfQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 17:17:57 FR0000044448 74 143.6000 EUR XPAR LYrgBkomTN-KCD70QG3ihgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 17:19:49 FR0000044448 58 143.4000 EUR XPAR 3453113724045 MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 17:19:49 FR0000044448 10 143.4000 EUR XPAR 3453113725045 MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 11/09/2026 17:19:49 FR0000044448 27 143.4000 EUR XPAR 3453113726045 MAR Art.5 §2c)  
                         
Verification  
  Quantité PMP
  0 #DIV/0!
  #REF! #REF!
  #REF! #DIV/0!

 

Attachment

Posted in UncategorizedTagged

Evaxion applies its AI-Immunology™ platform in autoimmune diseases

Posted on by Ravi Shankar
  • Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology™ to target underlying pathologies
  • The unique capabilities of AI-Immunology™ could potentially help develop new treatments with higher efficacy and less side effects than current treatments
  • Initial experimental data will be presented at the Protein & Antibody Engineering Summit (PEGS) Europe taking place in Lisbon, Portugal, on November 18, 2026

COPENHAGEN, Denmark, September 14, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI- Immunology™ platform, has begun the application of the platform in autoimmune diseases thereby expanding the company’s therapeutic focus and achieving another company milestone for 2026.

We are now conducting experimental testing of two novel AI-Immunology™ -based treatment concepts for autoimmune diseases. Both concepts could potentially offer higher efficacy and less side effects than currently available treatments as AI-Immunology™ has unique capabilities in addressing underlying disease pathologies with very high specificity.

AI-Immunology™ enables development of several novel therapeutic concepts focusing on disease modification. This carries substantial opportunities as autoimmune diseases are characterized by high unmet medical need with few treatment approaches focused on the underlying disease and offer significant partnership potential across all stages of drug development.

“We are very excited to apply AI-Immunology™ in a new disease area and validate these novel concepts, which could potentially target underlying disease biology rather than just symptoms. Autoimmune diseases can be severely debilitating and even lethal placing a massive burden on patients, relatives and society. With AI-Immunology™ we have unique opportunities to potentially improve treatment options in this area,” says Birgitte Rønø, CSO and COO of Evaxion.

Testing two different concepts 
Specifically, Evaxion is now testing a tolerogenic vaccine concept and an autoantibody binder concept. Data from the ongoing experiments will be presented at the Protein & Antibody Engineering Summit (PEGS) Europe taking place in Lisbon, Portugal, on November 18, 2026.

The tolerogenic approach involves vaccination with T-cell epitopes and co-delivery of immune modulators that direct the immune system to tolerance. AI-Immunology™ has unique capabilities in finding and prioritizing the best epitopes.

The autoantibody binder concept utilizes an antigen construct that captures autoantibodies, which are the main pathogenic drivers in many autoimmune diseases. Autoantibodies bind to 1 normal tissue causing tissue damage and/or blocking of key physiological functions. Thus, clearing of these autoantibodies is expected to treat the diseases.

Contact information 
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel drug candidates for cancer and infectious diseases. 

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development.

We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website.

Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further 2 discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.

Posted in UncategorizedTagged

ASML reports transactions under its current share buyback program

Posted on by Ravi Shankar

ASML reports transactions under its current share buyback program

VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML’s current share buyback program.

Date Total repurchased shares Weighted average price Total repurchased value
7-Sep-26 35,914 €1,491.99 €53,583,196
8-Sep-26 37,500 €1,511.91 €56,696,809
9-Sep-26 37,764 €1,493.80 €56,411,916
10-Sep-26 64,000 €1,464.34 €93,717,805
11-Sep-26 48,000 €1,478.20 €70,953,566

ASML’s current share buyback program was announced on 28 January 2026. Further details are available on our website.

This regular update of the transactions conducted under the buyback program is to be made public under the Market Abuse Regulation (Nr. 596/2014).

About ASML

ASML is a leading supplier to the semiconductor industry. The company provides chipmakers with hardware, software and services to mass produce the patterns of integrated circuits (microchips). Together with its partners, ASML drives the advancement of more affordable, more powerful, more energy-efficient microchips. ASML enables groundbreaking technology to solve some of humanity’s toughest challenges, such as in healthcare, energy use and conservation, mobility and agriculture. ASML is a multinational company headquartered in Veldhoven, the Netherlands, with offices across EMEA, the US and Asia. Every day, ASML’s more than 44,100 employees (FTE) challenge the status quo and push technology to new limits. ASML is traded on Euronext Amsterdam and NASDAQ under the symbol ASML. Discover ASML – our products, technology and career opportunities – at www.asml.com.

Media Relations contacts
Monique Mols, phone +31 6 528 444 18		 Investor Relations contacts
Jim Kavanagh, phone +31 40 268 3938
Pete Convertito, phone +1 203 919 1714
Peter Cheang, phone +886 3 659 6771

        

 

Posted in UncategorizedTagged

Oxford Lane Capital Corp. Provides August 2026 Net Asset Value Update

Posted on by Ravi Shankar

GREENWICH, Conn., Sept. 14, 2026 (GLOBE NEWSWIRE) — Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ) (NasdaqGS: OXLCN) (NasdaqGS: OXLCI) (NasdaqGS: OXLCG) (NasdaqGS: OXLCM) (the “Company,” “we,” or “our”) today announced the following net asset value (“NAV”) estimate as of August 31, 2026.

  • Management’s unaudited estimate of the range of the NAV per share of our common stock as of August 31, 2026, is between $10.34 and $10.64. This estimate is not a comprehensive statement of our financial condition or results for the month ended August 31, 2026. This estimate did not undergo the Company’s typical quarter-end financial closing procedures and was not approved by the Company’s board of directors. We advise you that our NAV per share for the quarter ending September 30, 2026 may differ materially from this estimate, which is given only as of August 31, 2026.
  • As of August 31, 2026, the Company had approximately 98.0 million shares of common stock issued and outstanding.

The fair value of the Company’s portfolio investments may be materially impacted after August 31, 2026, by circumstances and events that are not yet known. To the extent the Company’s portfolio investments are impacted by market volatility in the U.S. or worldwide, the Company may experience a material impact on its future net investment income, the fair value of its portfolio investments, its financial condition and the financial condition of its portfolio investments. Investing in our securities involves a number of significant risks. For a discussion of the additional risks applicable to an investment in our securities, please refer to the section titled “Risk Factors” in our prospectus and the section titled “Principal Risks” in our most recent annual report or semi-annual report, as applicable.

The preliminary financial data included in this press release has been prepared by, and is the responsibility of, Oxford Lane Capital Corp.’s management. The Company’s independent registered public accounting firm has not audited, reviewed, compiled, or applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, the Company’s independent registered public accounting firm does not express an opinion or any other form of assurance with respect thereto.

About Oxford Lane Capital Corp. 

Oxford Lane Capital Corp. is a publicly-traded registered closed-end management investment company principally investing in debt and equity tranches of CLO vehicles. CLO investments may also include warehouse facilities, which are financing structures intended to aggregate loans that may be used to form the basis of a CLO vehicle.

Forward-Looking Statements

This press release contains forward-looking statements subject to the inherent uncertainties in predicting future results and conditions. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements. These statements are not guarantees of future performance, conditions or results and involve a number of risks and uncertainties. Certain factors could cause actual results and conditions to differ materially from those projected in these forward-looking statements. These factors are identified from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to update such statements to reflect subsequent events, except as may be required by law.

Contact:
Bruce Rubin
203-983-5280

Posted in UncategorizedTagged

Total Energy Services Inc. Announces Changes to Board of Directors

Posted on by Ravi Shankar

CALGARY, Alberta, Sept. 14, 2026 (GLOBE NEWSWIRE) — Total Energy Services Inc. (“Total Energy” or the “Company”) (TSX:TOT) announces that Jessica Kirstine will retire from the Board of Directors on September 30, 2026. Total Energy thanks Ms. Kirstine for her significant contributions over the past five years.

Total Energy is pleased to announce that Elizabeth (Liz) Dammann has agreed to join the Board of Directors and will be appointed a director at the next Board of Directors’ meeting to be held in November 2026. Ms. Dammann is a professional engineer with over 25 years’ experience in the oil and gas industry, having served in various engineering and operational roles during her career. Ms. Dammann currently serves as the Vice President, Production and Capital Operations for Tundra Oil and Gas Ltd. Ms. Dammann has a Professional Engineering designation in Alberta (APEGA), Saskatchewan (APEGS) and Manitoba (EGM), obtained an Engineering degree from the University of Calgary in 2001 and a Master of Business Administration degree from Royal Roads University in 2025.

Headquartered in Calgary, Alberta, Total Energy provides contract drilling services, equipment rentals and transportation services, well servicing and compression and process equipment and service to the energy and other resource industries from operation centers in North America and Australia. The common shares of Total Energy are listed and trade on the TSX under the symbol TOT.

For further information, please contact Daniel K. Halyk, President and CEO at (403) 216-3921 or by e-mail at: investorrelations@totalenergy.ca or visit our website at www.totalenergy.ca.

The TSX has neither approved nor disapproved of the information contained herein.

Posted in UncategorizedTagged

etoro Reports Selected August Business Metrics

Posted on by Ravi Shankar

NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) — eToro Group Ltd. (“etoro”, or the “Company”) (NASDAQ: ETOR), the trading and investing platform, is reporting the below selected monthly business metrics for August 2026.

  • Assets under Administration (AUA) were $20.2B, up 3% year-over-year.
  • Funded Accounts* were 4.36M, up 18% year-over-year.
  • Capital Markets/ECC Activity
    • Total number of trades was 51.7M, up 31% year-over-year;
    • Invested amount per trade was $197, down 29% year-over-year;
  • Crypto Activity
    • Total number of trades was 5.3M, down 4% year-over-year;
    • Invested amount per trade was $97, down 70% year-over-year;
  • Interest Earning Assets were $7.1B, down 7% year-over-year.
  • Total Money Transfers was $1.2B, up 33% year-over-year.
  August**
  2025   2026   YoY Change
Trading Activity          
           
Number of trades (Capital markets/ECC) (in Millions) 39.4   51.7   31%
Invested amount per trade (Capital markets/ECC) $278   $197   -29%
Number of trades (Cryptoassets) (in Millions) 5.5   5.3   -4%
Invested amount per trade (Cryptoassets) $325   $97   -70%
           
Interest Earning Assets ($B) 7.6   7.1   -7%
           
Total Money Transfers ($B) 0.9   1.2   33%
           
           
AuA ($B) 19.7   20.2   3%
Funded Accounts (in Millions)* 3.69   4.36   18%

* Funded Accounts for August 2026 includes 110,000 from Zengo and Bit2C acquisitions.
** Metrics for August 2026 are estimated as of August 31, 2026. Numbers are rounded but percentages are based on unrounded numbers.

The selected preliminary data presented above is based on currently available information, has not been audited or reviewed, is subject to update and should not be extrapolated for future periods. Final results and other business metrics for the full fiscal quarter will be available in our filings with the U.S. Securities and Exchange Commission (“SEC”) or otherwise publicly disclosed and might vary from the information in this press release.

This press release includes key performance indicators that etoro’s management uses to help evaluate the business, measure its performance, identify trends, prepare financial projections and make business decisions. etoro’s key performance indicators include Funded Accounts, Assets under Administration Interest Earning Assets, Total Money Transfers and Number of Trades and Invested Amount per Trade, both for Cryptoassets and for Capital markets/ECC. Definitions of key performance indicators can be found at the end of this press release.

For more information, please see our presentation on our IR website at investors.etoro.com

etoro uses its website to distribute company information and makes available free of charge a variety of information for investors, including its filings with the SEC, in addition to disclosing information via press releases, filings with the SEC, public conference calls, webcasts, X feed (@etoro), Instagram page (@etoro_official) and LinkedIn page. The information disclosed through the foregoing channels could be deemed to be material information and we encourage investors, the media, and others to follow the channels listed above and to review the information disclosed through such channels. In addition, investors may opt in to automatically receive email alerts and other information about etoro when enrolling their email address under the “Stay Up to Date” option at the bottom of https://investors.etoro.com/. Information contained on or accessible through any of the foregoing channels is not incorporated by reference into this press release.

Definitions

Assets under administration (AUA): AUA reflects the aggregate fair value of assets held by users within the platform, including those held by third-party partners for execution or custody services, categorized as follows:

  • Crypto: Includes all cryptoassets held in etoro digital wallets, Zengo and Bit2C.
  • Equities: Includes stocks, ETFs, assets managed under the Spaceship program and ISA products.
  • Cash: Includes customers’ uninvested cash (e.g., cash balances, eMoney balances, in-process cashouts), as well as cash used for margin or posted as collateral for leveraged positions.

Funded Accounts: Funded Accounts are users who have successfully completed the onboarding requirements, activated their account, deposited funds, executed at least one trade, and maintain a positive account balance. For Zengo and Bit2C users, Funded Accounts are defined as users with a positive account balance. Funded Accounts represent the most advanced stage of our user acquisition funnel and are the primary source of commission-generating activity.

Interest Earning Assets: Interest Earning Assets are the average monthly balances of users’ cash balances, corporate cash, users’ total leveraged positions and stakeable cryptoassets.

Total Money Transfers: Total money transfers are the cumulative value across the respective period of user deposits, withdrawals, and cross-currency trade funding via etoro Money IBAN.

Trades: Trades represent the total number of orders that were placed by users and executed during the applicable period. Trades include self-directed and copy trades, and each trade reflects either the opening or closing of a position by a user.

Invested amount per trade: The total invested amount divided by the total number of trades. For reporting purposes, we present this measure separately for capital markets/ECC (equities, commodities, and currencies) and for cryptoassets, in order to highlight trends across the two categories, given their unique characteristics.

About etoro
etoro is the platform where you can trade, invest, save and spend. Founded in 2007 with the vision of a world where everyone can trade and invest in a simple and transparent way, we’ve built a regulated, Nasdaq-listed platform used by millions of people in 75 countries. We believe there is power in shared knowledge. By combining the collective intelligence of our community with AI-powered tools, we’ve created a collaborative investment community designed to help you grow your knowledge and wealth. On etoro, you can hold a range of traditional and innovative assets and choose how you invest: trade directly, invest in a portfolio, copy other investors, or invest with an AI agent.

Contact
Media Relations – pr@etoro.com
Investor Relations – investors@etoro.com

Posted in UncategorizedTagged

FactSet to Host Investor Day on November 10, 2026

Posted on by Ravi Shankar

NORWALK, Conn., Sept. 14, 2026 (GLOBE NEWSWIRE) — FactSet (NYSE: FDS | NASDAQ: FDS), a leading global intelligence and AI solutions provider to the financial markets, today announced that it will host an Investor Day on November 10, 2026, in New York City and via live webcast.

Sanoke Viswanathan, Chief Executive Officer, Josh Warren, Chief Financial Officer, and members of FactSet’s executive leadership team expect to discuss the Company’s strategy, product roadmap, and financial outlook, followed by a live question-and-answer session. The event will also showcase demonstrations of FactSet’s comprehensive solutions and broad set of AI-powered products.

FactSet Investor Day 2026 Details

Date: Tuesday, November 10, 2026
   
Time: 9:00 a.m. Eastern Time
   
Registration: FactSet Investor Day 2026
   

Registration for Investor Day is required. Presentation materials will be available on FactSet’s Investor Relations website at 8:30 a.m. Eastern Time on November 10, 2026, 30 minutes before the event begins. Following the event, a replay of the video webcast will be available for one year at investor.factset.com.

About FactSet

FactSet (NYSE: FDS | NASDAQ: FDS) supercharges financial intelligence, offering enterprise data and information solutions that help our clients maximize their potential. Our digital platform seamlessly integrates proprietary data, third-party sources, and flexible technology to deliver tailored solutions across the buy side, sell side, wealth, and corporate sectors. With over 47 years of expertise, we leverage advanced data connectivity, AI, and next-generation tools to streamline workflows and enable smarter decision-making. As an S&P 500 company serving more than 9,100 global clients and over 247,000 individual users, we are dedicated to innovation and long-term client success. Learn more at www.factset.com and follow us on X and LinkedIn.

Investor Relations:
Kevin Toomey
+1.212.209.5259
Kevin.toomey@factset.com

Media Relations:
Alexandra Shevchenko
+44 07518 131115
Oleksandra.shevchenko@factset.com

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance (opens in a new tab)
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.